Medicine:Calibrated automated thrombogram
The calibrated automated thrombogram (CAT or CT) is a thrombin generation assay (TGA) and global coagulation assay (GCA) which can be used as a coagulation test to assess thrombotic risk.[1][2] It is the most widely used TGA.[3] The CAT is a semi-automated test performed in a 96-well plate and requires specialized technologists to be performed.[3] As a result, it has seen low implementation in routine laboratories and has been more limited to research settings.[3][4] Lack of standardization with the CAT has also led to difficulties in study-to-study comparisons in research.[3][5] However, efforts have recently been made towards standardization of the assay.[5][6][7][8] An example of a specific commercial CAT is the Thrombinoscope by Thrombinoscope BV (now owned by Diagnostica Stago).[9] The CAT can be used to measure thrombogram parameters such as the endogenous thrombin potential (ETP)[2][10] and to assess activated protein C resistance (APCR).[5] The CAT ETP-based APC resistance test is especially sensitive to estrogen-induced procoagulation, such as with combined oral contraceptives.[2][5][11]
In 2018, a commercial fully-automated TGA system and alternative to the CAT called the ST Genesia debuted.[3] It has been said that this system should allow for more widespread adoption of TGAs in clinical laboratories.[3][12] The ST Genesia system also shows improved reproducibility compared to the CAT.[3]
References
- ↑ "The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability". Pathophysiol Haemost Thromb 32 (5–6): 249–53. 2002. doi:10.1159/000073575. PMID 13679651.
- ↑ 2.0 2.1 2.2 "Global coagulation assays in hypercoagulable states". J Thromb Thrombolysis 54 (1): 132–144. January 2022. doi:10.1007/s11239-021-02621-1. PMID 34997471.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?". Hamostaseologie 40 (3): 364–378. August 2020. doi:10.1055/a-1153-5824. PMID 32726831.
- ↑ "Global Coagulation Assays in Transgender Women on Oral and Transdermal Estradiol Therapy". J Clin Endocrinol Metab 105 (7): e2369–e2377. July 2020. doi:10.1210/clinem/dgaa262. PMID 32413907.
- ↑ 5.0 5.1 5.2 5.3 "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk". Front Endocrinol (Lausanne) 12: 769187. 2021. doi:10.3389/fendo.2021.769187. PMID 34956081.
- ↑ "Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need". Clin Chem Lab Med 58 (2): 294–305. January 2020. doi:10.1515/cclm-2019-0471. PMID 31444961.
- ↑ "Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance". J Thromb Haemost 18 (4): 895–904. April 2020. doi:10.1111/jth.14745. PMID 31984653.
- ↑ "Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay". Res Pract Thromb Haemost 5 (7): e12612. October 2021. doi:10.1002/rth2.12612. PMID 34761157.
- ↑ "A review of commercially available thrombin generation assays". Res Pract Thromb Haemost 2 (1): 42–48. January 2018. doi:10.1002/rth2.12048. PMID 30046705.
- ↑ "Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations". Rev Bras Hematol Hemoter 39 (3): 259–265. 2017. doi:10.1016/j.bjhh.2017.03.009. PMID 28830606.
- ↑ "Mechanisms of estrogen-induced venous thromboembolism". Thromb Res 126 (1): 5–11. July 2010. doi:10.1016/j.thromres.2010.01.045. PMID 20163835.
- ↑ "Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing". Semin Thromb Hemost 45 (3): 228–246. April 2019. doi:10.1055/s-0038-1676579. PMID 30912101.
 |  |
